Wagner Bowman Management Corp increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 47,171 shares of the company’s stock after purchasing an additional 1,452 shares during the period. Johnson & Johnson makes up 1.7% of Wagner Bowman Management Corp’s portfolio, making the stock its 11th largest holding. Wagner Bowman Management Corp’s holdings in Johnson & Johnson were worth $6,132,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of JNJ. Harding Loevner LP acquired a new stake in shares of Johnson & Johnson during the second quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the period. IHT Wealth Management LLC lifted its holdings in Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc acquired a new stake in Johnson & Johnson in the second quarter valued at $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new stake in Johnson & Johnson in the second quarter valued at $177,000. 67.35% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have commented on JNJ shares. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. BMO Capital Markets raised their target price on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 target price for the company in a report on Wednesday, December 20th. JPMorgan Chase & Co. downgraded Johnson & Johnson from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Finally, Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Four analysts have rated the stock with a sell rating, nine have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $146.26.
In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the transaction, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.19% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) opened at $133.68 on Friday. Johnson & Johnson has a 52-week low of $120.95 and a 52-week high of $148.32. The firm has a market capitalization of $358,650.34, a price-to-earnings ratio of 18.31, a PEG ratio of 2.13 and a beta of 0.77. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The business had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. During the same quarter last year, the business posted $1.58 earnings per share. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. sell-side analysts forecast that Johnson & Johnson will post 8.11 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.51%. The ex-dividend date of this dividend was Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 861.54%.
ILLEGAL ACTIVITY WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/18/wagner-bowman-management-corp-buys-1452-shares-of-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.